Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
Tissue Engineering and Regenerative Medicine
;
(6): 371-387, 2023.
Article
in English
| WPRIM
| ID: wpr-1003161
ABSTRACT
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Tissue Engineering and Regenerative Medicine
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS